ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
AbSci Corporation

AbSci Corporation (ABSI)

2.855
-0.365
(-11.34%)
Closed 13 January 8:00AM
2.91
0.055
(1.93%)
After Hours: 11:59AM

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

ABSI News

Official News Only

ABSI Discussion

View Posts
Bandicoot_Inv Bandicoot_Inv 18 hours ago
https://www.technologynetworks.com/drug-discovery/articles/how-is-ai-being-used-in-drug-discovery-394789
πŸ‘οΈ0
Bandicoot_Inv Bandicoot_Inv 2 days ago
Absci and Owkin Synergize Leading TechBio Platforms to Advance Generative AI Drug Discovery
07:30:00 AM ET, 01/10/2025 - GlobeNewswire

VANCOUVER, Wash. and PARIS, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, and Owkin, a TechBio that uses agentic AI to unlock complex targets for drug discovery, development, and diagnostics, today announced a partnership bringing together two leading AI platforms to rapidly discover and design novel therapeutics for patients.

β€œAt Absci, we’re constantly pushing the boundaries of innovation to bring better biologics to patients faster,” said Sean McClain, Founder and CEO of Absci. β€œBy combining Absci’s AI de novo design expertise with Owkin’s world-class predictive AI target discovery technology, we have a unique opportunity to design first-in-class and potentially transformative therapeutics for patients in need.”

Through this strategic partnership, Absci and Owkin will co-develop therapeutic candidates addressing novel targets in immuno-oncology and other indications, such as immunology and inflammation. Owkin’s predictive AI models will optimize target selection and validate therapeutic hypotheses using extensive biomedical datasets and patient-derived organoids. Absci’s generative AI Drug Creation platform, including its de novo antibody design models, will rapidly design therapeutic candidates against these novel targets. Together, the companies will aim to streamline and accelerate the path from research to clinical development.

β€œAt Owkin, our mission is to use patient data and Owkin K, our Operating System, to revolutionize drug discovery and development,” said Thomas Clozel, MD, CEO and Co-Founder of Owkin. β€œThis partnership with Absci represents a significant step forward in our journey to bring transformative therapies to patients. By bringing together Owkin’s AI agents that can identify and experimentally validate novel therapeutic targets with Absci’s pioneering capabilities in developing biologic drug candidates, we aim to accelerate the delivery of next-generation treatments.”

This collaboration builds on Absci’s growing portfolio of partnerships with industry leaders such as AstraZeneca and Merck, as well as its robust internal pipeline of drug candidates. With this new partnership, Absci has added drug creation partnerships with four new Partners in 2024, achieving the Company's outlook for the year. Similarly, Owkin has established itself as a pioneer in predictive AI, working with top-tier pharmaceutical companies such as Sanofi and BMS to advance drug discovery and development as well as its differentiated pipeline of drug candidates and AI diagnostics
πŸ‘οΈ0
Bandicoot_Inv Bandicoot_Inv 2 days ago
ProMIS Neurosciences (PMN) announced the initiation of its Phase 1b clinical trial evaluating its lead therapeutic candidate, PMN310, in Alzheimer's disease.Absci Corporation (ABSI) announced a partnership bringing together two leading AI platforms to rapidly discover and design novel therapeutics for patients.Tourmaline Bio (TRML) announced that Paul M. Ridker, MD, MPH, Eugene Braunwald Professor of Medicine at the Harvard Medical School and Director of the Center for Cardiovascular Disease Prevention at Brigham and Women's Hospital, has joined Tourmaline's Cardiovascular Scientific Advisory Board.
πŸ‘οΈ0
Bandicoot_Inv Bandicoot_Inv 4 days ago
AMD is investing $20 million in AI drug startup Absci , which will use AMD chips and software
πŸ‘οΈ0
Bandicoot_Inv Bandicoot_Inv 4 days ago
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Absci (NASDAQ:ABSI) with a Buy and maintains $7 price target.
πŸ‘οΈ0
Invest-in-America Invest-in-America 4 days ago
ABSI: I'm in --- nice deal with AMD!!
πŸ‘οΈ0
ANTADOG ANTADOG 2 months ago
3rd quarter results Nov. 12, fyi ANT
πŸ‘οΈ0
ANTADOG ANTADOG 3 months ago
2025 gettin' closer, ANT
πŸ‘οΈ0
ANTADOG ANTADOG 3 months ago
Approachin' the end of the 6 month tradin' channel, gets interestin' now, fyi imvho ANT
πŸ‘οΈ0
Monksdream Monksdream 3 months ago
C
A prescription drug bottle filled with 0s and 1s to represent binary code.Francis Scialabba
CFOs are embracing AI, experimenting with new use cases for it throughout the finance function. But some CFOs are tapping the potential of the technology in other ways. At biotech firm Absci, researchers are using AI to develop drugs to treat cancer. (We’re not saying that to make your Claude-drafted emails look bad, we promise.)

Absci’s CFO and CBO, Zach Jonasson, spoke with CFO Brew about how AI is allowing the company to create and test new antibodies fasterβ€”and cheaperβ€”than ever before.

Absci uses E. coliβ€”yes, the same bacteria that can give you some nasty infectionsβ€”to manufacture antibodies that can be used in a variety of therapies. Using a process called β€œhigh throughput screening,” it then tests the antibodies, and it patents therapies containing the most promising ones.

Even before ChatGPT burst onto the scene, Absci saw potential in AI. Through its testing of antibodies, the company generated large amounts of data, which it realized could be used to train an AI. In 2021, it acquired a deep learning company called Denovium, which became β€œthe nucleus” that it built a proprietary AI around, Jonasson said.
πŸ‘οΈ0
Monksdream Monksdream 4 months ago
ABSI under $5
πŸ‘οΈ0
Monksdream Monksdream 5 months ago
ABSI three month chart
πŸ‘οΈ0
Dharna Dharna 5 months ago
Been 1 year since thus post and what a nice investment. Up 105% I'll take that all day and year long.

It will only take one success to be multi millions
πŸ‘οΈ0
Dharna Dharna 5 months ago
It only takes one success..
Now we're in the cancer realm
My call 8.59 before end of year
πŸ‘οΈ0
ANTADOG ANTADOG 6 months ago
touchin' resistance, anyday now imfho ANT
πŸ‘οΈ0
ANTADOG ANTADOG 6 months ago
Canada: only 2 things i keep in mind: golden Maple leafs and a master chartist, a magic combo, ANT
πŸ‘οΈ0
ANTADOG ANTADOG 6 months ago
moderate volume last few tradin' days but holdin' onto that nice area on the chart, ANT
πŸ‘οΈ0
ANTADOG ANTADOG 6 months ago
testin' resistance for the 5th time, this puppy wants to move imvho ANT
πŸ‘οΈ0
ANTADOG ANTADOG 6 months ago
imo now it breaks that first resistance at 4,50 are we'll temporarily be hooverin' back to the 50ma area, imo and fyi ANT
πŸ‘οΈ0
ANTADOG ANTADOG 6 months ago
4th time knockin' on them 4,50's, it's not if but when it will pierce thru, ANT
πŸ‘οΈ0
ANTADOG ANTADOG 6 months ago
recoverin' above 50ma, co is busy, 2025 should be great, meanwhile, we have 4,50 and 5,00 as nxt resistances, patience, ANT
πŸ‘οΈ0
ANTADOG ANTADOG 6 months ago
today was third time it tried to break resistance (4,50), comin' down it bounced of that 50ma line perfectly, patience, it is a nice consolidation process so far, ANT
πŸ‘οΈ0
ANTADOG ANTADOG 6 months ago
some consolidation just above that 50ma should give us more strength later, jmfho ANT
πŸ‘οΈ0
ANTADOG ANTADOG 6 months ago
2 million+ volume again today, xcellent so far, ANT
πŸ‘οΈ0
ANTADOG ANTADOG 6 months ago
needs just a bit more volume to break 4,5 resistance imo, patience is key, ANT
πŸ‘οΈ0
ANTADOG ANTADOG 6 months ago
and hit now, ANT
πŸ‘οΈ0
ANTADOG ANTADOG 6 months ago
daily avg vol in, want to see if 4,50 gets broken, ANT
πŸ‘οΈ0
ANTADOG ANTADOG 6 months ago
first things first, added some under 4 bucks, patience, ANT
πŸ‘οΈ0
ANTADOG ANTADOG 6 months ago
curious about the nxt resistance at 4,50, looks good so far, ANT
πŸ‘οΈ0
ANTADOG ANTADOG 6 months ago
50ma magnet? Let's see, ANT
πŸ‘οΈ0
ANTADOG ANTADOG 6 months ago
Absci to Report Business Updates and Second Quarter 2024 Financial and Operating Results on August 14, 2024 fyi ANT
πŸ‘οΈ0
ANTADOG ANTADOG 6 months ago
daily volume intact for awhile now, fyi ANT
πŸ‘οΈ0
ANTADOG ANTADOG 6 months ago
https://www.absci.com/gen-absci-eyes-busy-2025-as-lead-ai-designed-candidate-heads-for-clinic/
fyi ANT
πŸ‘οΈ0
Monksdream Monksdream 7 months ago
ABSI
πŸ‘οΈ0
ANTADOG ANTADOG 8 months ago
5,25~~ ANT
πŸ‘οΈ0
ANTADOG ANTADOG 9 months ago
Hello 5's again, ANT
πŸ‘οΈ0
TrendTrade2016 TrendTrade2016 9 months ago
ALGO POP....GOT OUT HERE!!
πŸ‘οΈ0
TrendTrade2016 TrendTrade2016 9 months ago
ABSI..IS NOW A WEEKLY BREAK OUT PLAY
πŸ‘οΈ0
ANTADOG ANTADOG 9 months ago
ABSI cruisin', one of my longterm holds, ANT
πŸ‘οΈ0
Monksdream Monksdream 9 months ago
ABSI new 52 hi
πŸ‘οΈ0
ANTADOG ANTADOG 9 months ago
6,50~~ ANT
πŸ‘οΈ0
ANTADOG ANTADOG 9 months ago
Hello 6 bucks, ANT
πŸ‘οΈ0
ANTADOG ANTADOG 9 months ago
5,71~~ ANT
πŸ‘οΈ0
ANTADOG ANTADOG 9 months ago
Behaves like a lowfloater should, 5,56~~ ANT
πŸ‘οΈ0
ANTADOG ANTADOG 9 months ago
churn above 5 bucks continues, first trial update will heat this one up for sure, had a nice long weekend despite the weather, it's my cold Nordland for a reason lol, ANT
πŸ‘οΈ0
ANTADOG ANTADOG 10 months ago
sweet vol again, 5,69~~ ANT
πŸ‘οΈ0
ANTADOG ANTADOG 10 months ago
5,54~~ have no doubt about my 2024 stocks, ANT
πŸ‘οΈ0
ANTADOG ANTADOG 10 months ago
Good volume so far, almost 600k shares after 150 minutes of tradin', i'll take it, ANT
πŸ‘οΈ0
ANTADOG ANTADOG 10 months ago
the churn around 5 bucks brought strength, 5,56~~ hod so far, ANT
πŸ‘οΈ0
ANTADOG ANTADOG 10 months ago
Double digit stock eoy or sooner: Initiated IND-enabling studies for ABS-101, a potential best-in-class anti-TL1A antibody
Entered into collaboration with AstraZeneca for up to $247M in deal value, plus royalties

Strengthened balance sheet raising approximately $86M in gross proceeds through underwritten common stock offering
fyi ANT
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock